Sertraline treatment of hallucinogen persisting perception disorder.
Young
C R
CR
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000506:poisoning*; D008297:Male; D010468:Perceptual Disorders / Q000139:chemically induced* / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D020280:Sertraline; D019966:Substance-Related Disorders / Q000150:complications; D014796:Visual Perception / Q000187:drug effects*
D015057:1-Naphthylamine; D000928:Antidepressive Agents; D008238:Lysergic Acid Diethylamide; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline